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Editorial on the Research Topic
Podocyte Pathology and Nephropathy—An Update
Dysfunction and loss of glomerular podocytes have been found to be the driving forces leading to
the development of the majority of the forms of chronic kidney disease (CKD) (1, 2). Podocytes
are unique cells not only in their complex form and function, but also due to their inability to
proliferate and replenish the lost podocytes in themature kidney. Since podocyte loss is irreversible,
development of podocyte-protective therapies is of particular importance. The previous Research
Topic on Podocyte Pathology and Nephropathy (3) covered diagnostic approaches and novel
therapeutic strategies for early detection of and protection from podocyte injury. In the current
issue, the authors present up-to-date findings on the potential targets for podocyte-specific drugs as
well as on mechanisms underlying podocyte and kidney impairment. Particular emphasis is given
to molecular mechanisms that may contribute to the pathogenesis of diabetic podocytopathy.
Diabetes is the most common cause of CKD and end-stage renal disease worldwide. Multiple
pathways triggered by hyperglycemia in different tissues have also been observed to be active in
podocytes. Podocyte injury is pivotal for the loss of renal function and, in line with this, podocytes
are considered to be one of the weakest players in the kidney homeostasis disturbed in diabetic
kidney disease (DKD) (4). Nevertheless, our knowledge on the pathophysiological mechanisms
leading to podocyte injury and development of DKD is still incomplete. A recent study shed
new light on this by sub-categorizing the patients with diabetes to distinct groups based on six
clinical variables, revealing that severely insulin resistant patients with diabetes are at high risk
to develop DKD (5). As highlighted by Lay and Coward, insulin modulates several physiological
responses in podocytes, and insulin resistance has multiple consequences that contribute to
podocyte impairment and the development of DKD. In line with this, podocyte-specific deletion
of insulin receptor leads to the development kidney injury resembling DKD even though the mice
remain normoglycemic. The pathomechanisms of insulin resistance in podocytes include defective
action of nephrin, a protein expressed in the slit diaphragm and essential for the function of the
glomerular filtration barrier. Nephrin can directly interact with the insulin receptor, and thereby
may regulate its function and impact on insulin-dependent effects in podocytes. The authors
also discuss the role of epigenetic modifications in the control of podocyte insulin signaling, and
highlight the links between insulin signaling, endoplasmic reticulum stress, and mitochondrial
function in DKD.
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The intracellular level of glucose in podocytes is regulated by
facilitative glucose transporters (GLUTs) similarly as in other
insulin responsive cells. However, as indicated by Wasik and
Lehtonen, the roles of GLUT proteins in the development of
DKD seem to vary depending on the GLUT and the cell type in
which it is expressed. Whereas, overexpression of GLUT1 and
knockout of GLUT4 specifically in podocytes have been shown to
protect against the development of DKD, high GLUT1 expression
in mesangial cells is associated with the progression of DKD.
Efficacy of glucose uptake by GLUTs is tightly correlated with the
activity of the pathways that regulate the trafficking of GLUTs
between the intracellular stores and the plasma membrane.
Notably, nephrin participates in the control of the intracellular
trafficking of GLUTs via interactions with the regulatory
proteins. The present study by Lewko et al. further shows
that the surface expression of GLUT1, GLUT2, and GLUT4
correlates with glucose uptake in podocytes and is directly
regulated by angiotensin II (AngII). GLUT1- and GLUT4-
mediated glucose transport depends on insulin-triggered
signaling which is interfered by AngII. In hyperglycemic milieu
glucose uptake in podocytes becomes insensitive to insulin
but not to AngII.
Initially considered to be mainly a structural protein of the
filtration barrier, nephrin appears to play far more complex roles
in podocytes. In addition to mediating insulin-induced actions
in podocytes as described above, nephrin, via phosphorylation
of its various tyrosine and threonine residues, forms complexes
with many proteins, as pointed out by Martin and Jones.
Signaling networks established this way enable dynamic control
of various cellular processes, including, for example, modulation
of the actin cytoskeleton dynamics and mechanosensing, and
thereby regulation of podocyte morphology and glomerular
barrier function. Phosphorylation of nephrin regulates its
endocytosis, and interestingly, nephrin trafficking both from
the endoplasmic reticulum to the plasma membrane as well
as from the plasma membrane back to the intracellular
compartment are essential for the function of nephrin. The
authors of the article thus propose that aberrant trafficking
of nephrin may be a central mechanism of nephrin-associated
kidney diseases.
Interorgan crosstalk is considered exceedingly important
in the development of various diseases, including CKD. In
their article Lehto and Groop describe gut-kidney interorgan
crosstalk linking the gastrointestinal tract and the pathogenesis
of nephropathy and associated podocyte injury. Gut with its
microbiota forms the largest interface between the individual
and the outside world. Not only nutrition, but also whole-
body immunity depends on the condition of the gastrointestinal
tract. It is now clear that disruption of the gastrointestinal
wall and gut dysbiosis, or altered gut bacterial composition, are
associated with translocation and accumulation of nephrotoxic
compounds. Dysregulation of the whole-body immune system by
alterations of the gut microbiota increases the risk of certain types
of kidney disease. Based on putative interconnections between
gastrointestinal and renal disorders, renoprotective effects of
dietary interventions including probiotic and resistant starch
supplementation as well as transplantation of fecal microbiota
are discussed. Also potential novel therapeutic targets are
introduced. In addition to the gut-kidney axis, interactions
between adipose tissue and kidney (6) as well as between liver and
kidney (7) play a role in normal kidney function and in response
to kidney injury.
Studying podocyte biology using cells cultured in the two-
dimensional system has inherent limitations. As highlighted by
Lal and Patrakka, the ideal research model should recapitulate
the basement membrane that is sandwiched between the
layers of podocytes and endothelial cells. Thus, direct
monitoring of podocytes in vivo would be the optimal tool
for analyzing the morphology and behavior of these highly
specialized cells. So far, due to optical resolution limits,
electron microscopy has been the tool of choice to study
podocyte foot processes and their altered morphology in
disease states. However, recent years have brought about
the development of different super-resolution microscopic
techniques enabling significant new insights into podocyte
morphology. Novel microscopy approaches and improved
methods for sample preparation have allowed visualization of
the morphological details of the podocytes and observation
of podocyte behavior in situ. In their review, Siegerist et
al. present current options for podocyte research using the
latest microscopic techniques, including three-dimensional
structured illumination microscopy (3D-SIM), stimulated
emission depletion microscopy (STED), stochastic optical
reconstruction microscopy (STORM), and photoactivated
localization microscopy (PALM). In addition, multiphoton
microscopy (MPM) and light-sheet/selective plane illumination
microscopy (SPIN), allowing intravital imaging of podocytes,
are described.
The title of the review by Lal and Patrakka, “Understanding
podocyte biology to develop novel kidney therapeutics,” is the
best summary of the aims and the content of this Research
Topic. In search for novel therapeutics, the researchers are
balancing between the high throughput models with low
physiological relevance, such as two-dimensional cultures of
immortalized podocytes, and low throughput models with high
physiological relevance, including variousmodel organisms. New
options in the form of microphysiological systems and kidney
organoids may pave the way for identifying new treatment
targets and validating drug leads. Concomitantly, revealing new
mechanisms, signaling pathways and interactions, accompanied
by improved experimental models and novel monitoring
techniques, can accelerate the development of podocyte-specific
kidney therapies.
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